Add
NPSP to Portfolio
Set Alert
Email to a
Friend
| |||
|
|
Quotes & Info
|
| NPSP > SEC Filings for NPSP > Form 8-K on 14-Jul-2003 | All Recent SEC Filings |
14-Jul-2003
Other Events and Financial Statements & Exhibits
On July 9, 2003, NPS Pharmaceuticals, Inc. (the "Company"), issued a press release announcing that the initial purchasers of $170 million principal amount of its 3% Convertible Notes due 2008 had elected to exercise their option to purchase an additional $22 million principal amount of such Notes. As a result, the final aggregate principal amount of the offering of the Notes is $192 million. These Notes are convertible into NPS Pharmaceuticals, Inc. common stock at a conversion price of approximately $36.59 per share (reflecting a 35% premium relative to the NASDAQ closing price for the Company's common stock of $27.10 on June 11, 2003). The placement of the additional Notes closed on July 11, 2003. A copy of the Company's press release issued on July 9, 2003 pursuant to Rule 135c of the Securities Act is attached as Exhibit 99.1 hereto and is incorporated herein by reference.
The securities described in this Form 8-K have not been registered under the Securities Act, or any state securities laws, and may not be offered or sold in the United States absent registration under, or an applicable exemption from, the registration requirements of the Securities Act and applicable state securities laws. This Form 8-K does not constitute an offer to sell these securities nor is it a solicitation of an offer to purchase these securities. The statements in this Form 8-K regarding future aspects relating to the offering and other statements which are not historical facts are forward-looking statements that involve risks and uncertainties, including, but not limited to, market and competitive conditions, that may cause actual future experience and results to differ materially from the statements made.
(c) Exhibits:
Exhibit Description - -
99.1 Press Release of NPS Pharmaceuticals, Inc. dated July 9,
2003, issued pursuant to Rule 135c of the Securities Act.
|
|